Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trained immunity induced by intravesical BCG in high-risk non-muscle invasive bladder cancer
NL-OMON47732Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bcg vaccine in bladder cancer and transitional cell carcinoma (TCC), sponsored by Radboud University Medical Center. Primary endpoints: Epigenetic trained immunity markers in circulating monocytes, Ex vivo monocyte cytokine production and 3 more. Started Jun 2018; status: active, not recruiting.
02
Drugs
bcg vaccine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON47732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47732.